Phathom Pharmaceuticals (PHAT) Change in Receivables (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Change in Receivables for 4 consecutive years, with $16.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Receivables rose 12.13% year-over-year to $16.7 million; the TTM figure through Jun 2026 stood at $46.2 million (up 14.33% YoY), while the FY2025 annual figure was $39.3 million, up 5.84% from the prior year.
• Change in Receivables climbed to $16.7 million in Q2 2026 per PHAT's latest filing, from $2.6 million in the prior quarter.
• Across five years, Change in Receivables topped out at $22.3 million in Q4 2025 and bottomed at -$2.4 million in Q1 2025.
• Historically, Change in Receivables has averaged $8.9 million across 4 years, with a median of $7.0 million in 2024.
• Annual changes were most pronounced in 2024 — Change in Receivables surged 984.0% — and 2025, when it plunged 208.47%.
• Phathom Pharmaceuticals' Change in Receivables stood at $1.6 million in 2023, then soared by 984.0% to $17.7 million in 2024, then gained by 25.89% to $22.3 million in 2025, then dropped by 25.26% to $16.7 million in 2026.
• Business Quant data shows PHAT's Change in Receivables at $16.7 million in Q2 2026, $2.6 million in Q1 2026, and $22.3 million in Q4 2025.